Friday 04 Apr, 2025 09:33 PM
Site map | Locate Us | Login
   Ujjivan SFB rises after total deposits climb 20% YoY in Q4    Market tumble for 2nd day amid trump tariffs decision; border mkt underperforms    HUDCO board OKs to raise upto Rs 65,000 crore in FY26    DMart revenue jumps 17% YoY in Q4 FY25    Garware Hi Tech Films Ltd leads losers in 'A' group    Pearl Global Industries Ltd leads losers in 'B' group    Torrent Power arm incorporates wholly owned subsidiary    Yes Bank's loan book rises to Rs 2.46 lakh crore in Q4 FY25; deposits up 7% YoY    Volumes spurt at Rainbow Childrens Medicare Ltd counter    Emcure Pharma's European arm acquires Manx Healthcare for '19.7 million    Metal stocks edge lower    Reliance Industries Ltd slips for fifth straight session    J&K Bank records 11% YoY growth in gross advances in Q4 FY25    IEX records 18% YoY rise in traded electricity volume in Q4 FY25    Vedanta records aluminium production of 6.03 lakh tonnes in Q4 
Saravan Stocks
       
Company News
Quality Power Electrical Equipments Ltd
Stock Alert: RPP Infra, Zydus Life, Shilpa Medicare, Quality Power, Alkem Lab
Mar 17,2025   Hrs IST

Securities in F&O Ban:

BSE, IndusInd Bank, Hindustan Copper, Manappuram Finance and SAIL shares are banned from F&O trading on Monday, 17 March 2025.

Stocks to Watch:

Quality Power Electrical Equipment’s consolidated net profit jumped 23% to Rs 13.83 crore in Q3 FY25 as compared with Rs 11.24 crore. Net sales declined 48.9% YoY to Rs 72.59 crore during the quarter ended 31st December 2024.

RPP Infra Projects received a letter of acceptance for a new project worth Rs 22.56 crore from the Department of Space Centre, Construction and Maintenance Group, Sriharikota.

Zydus Lifesciences announced that the US Food and Drug Administration (USFDA) conducted a surveillance inspection at the company’s Active Pharmaceutical Ingredient (API) Unit 1, located in Ankleshwar, Gujarat.

Shilpa Medicare announced that the United States Food and Drug Administration (USFDA) conducted an inspection at Unit-2 of its subsidiary, Shilpa Pharma Lifesciences, located in Raichur, with zero observations.

Tata Communications announced the appointment of N. Ganapathy Subramaniam as the chairman of the board of directors of the company, effective from 14 March 2025.

JB Chemicals & Pharmaceuticals’ API (Active Pharmaceutical Ingredient) manufacturing facility (D9) in Panoli, Gujarat, successfully cleared a US Food and Drug Administration (USFDA) inspection without any observations.

G R Infraprojects announced that it has been selected as the preferred bidder for the Agra-Gwalior Greenfield Road Project, tendered by the National Highways Authority of India (NHAI) under the Ministry of Road Transport and Highways.

Alkem Laboratories announced that the United States Food and Drug Administration (USFDA) conducted a Bioresearch Monitoring (BIMO) inspection at its Bioequivalence Center in Taloja, Maharashtra, from 10 March to 13 March 2025.

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 39979673
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd